Background and objective: Criteria for interstitial pneumonia with autoimmune features (IPAF) were recently established for research purposes in a joint statement from the European Respiratory Society (ERS) and American Thoracic Society (ATS). We reviewed the utility of these criteria in patients previously diagnosed as broadly defined undifferentiated connective tissue disease (UCTD) and noted overlapping IPAF findings. Additional review was given to IPAF patients with usual interstitial pneumonia (UIP) on histopathology or radiology in terms of survival and outcome. Methods: Patients with prior UCTD-interstitial lung disease (ILD) were screened by ERS/ATS criteria for IPAF. Clinical data along with all-cause mortality were collated and compared with selected idiopathic pulmonary fibrosis (IPF) patients from the same study period. Survival was compared between IPAF subgroups with and without UIP features. Results: One hundred and one UCTD-ILD subjects (91%) evaluated from 2005 to 2012 also met strict criteria for IPAF. Frequent clinical findings included Raynaud's phenomenon, positive anti-nuclear antibody (ANA) and non-specific interstitial pneumonia (NSIP) pattern on chest computed tomography (CT). Nineteen had features of UIP either on histopathology or CT imaging. As compared with IPF, IPAF patients had overall better survival except in those with UIP features. Conclusion: Current IPAF criteria encompassed the majority of broadly defined UCTD-ILD and included those with UIP findings. Survival compared with IPF in those with UIP was similar. Further studies are necessary to refine IPAF definitions for clinical use and guide directed management strategies.
INTRODUCTION
Clinicians often encounter patients with interstitial lung disease (ILD) and autoimmune features not meeting diagnostic criteria for connective tissue disease (CTD). These were previously categorized as undifferentiated CTD (UCTD) using limited or broad definitions. 1, 2 What is less clear and a current point of investigation is whether such patients, who are thought to develop ILD via autoimmune processes similar to their confirmed CTD counterparts, have similar favourable prognoses. 3, 4 Several teams of investigators have worked independently to define and assess survival in this population using various diagnostic criteria. 1, [5] [6] [7] A joint task force from the European Respiratory Society (ERS) and American Thoracic Society (ATS) has recently redefined diagnostic criteria for this subset of patients now termed interstitial pneumonia with autoimmune features (IPAF). 8 Although derived as a clinical entity, the authors suggested not using current definitions for clinical practice but more as a means to
SUMMARY AT A GLANCE
Interstitial pneumonia with autoimmune feature (IPAF) criteria were recently established to clarify research definitions for interstitial lung disease (ILD) patients with features of autoimmune disease. Our study found these criteria encompassed the majority of patients previously diagnosed as UCTD-ILD and did not exclude radiological or histological usual interstitial pneumonia (UIP) (IPAF with UIP features), whose survival was indistinguishable from idiopathic pulmonary fibrosis (IPF). establish research criteria. 8, 9 Questions remain as to the applicability of current IPAF definitions to other suspected disease entities where overlap may be significant and lead to diagnostic uncertainty. Which criteria may need to be further refined due to clinical or logistic impracticalities, and whether certain pathological or radiological subsets offer more or less favourable outcomes remain of interest. Recent findings suggest those with features of usual interstitial pneumonia (UIP) (which are not formally excluded from IPAF diagnosis if other domain criteria are met) have similarly poor outcomes comparable to idiopathic pulmonary fibrosis (IPF). 10 The purpose of our study was to assess the incidence of overlap with previously diagnosed UCTD and IPAF and confirm whether differences in survival exist among those with or without UIP features on pathology or computed tomography (CT).
METHODS
Institutional review board approval was obtained (IRB# . Patients seen at Mayo Clinic Rochester from 1 January 2005 through 31 December 2013 were screened from the electronic medical record using search terms 'undifferentiated connective tissue disease' and 'interstitial lung disease'(UCTD-ILD). A screening panel of 132 patients met search criteria with sufficient clinical follow-up of >2 years. Eleven were eliminated on the basis of not having a discernible interstitial process on CT at the time of diagnosis or in follow-up. Ten others had concomitant or subsequent CTD diagnoses based on final rheumatologist consultation. The remaining 111 were confirmed UCTD-ILD diagnoses at the time of clinical presentation using the broad definition proposed by Kinder et al.
2 (see Table 1 for broad definition of UCTD vs IPAF). IPAF was defined by strict statement criteria requiring positive findings in ≥2 of the three domains (Clinical, Serologic and Morphologic) after exclusion of other known or secondary causes 8 (Table 1) . Of the 111 UCTD-ILD reviewed for the presence or absence of IPAF criteria, an additional 10 were excluded for not meeting strict IPAF disease definitions. Clinical documentation was reviewed for positive signs or symptoms fitting the Clinical Domain, with positive serology from within and outside the institution included for the Serologic Domain. Radiology and pathology reports along with pulmonary function test (PFT) and echocardiography were reviewed for positive features supporting the Morphologic Domain. Each CT imaging study was reviewed by the authors for the purposes of this study and classified as consistent or possible radiological UIP based on the 2011 international consensus, 11 with other radiological patterns (non-specific interstitial pneumonia (NSIP), organizing pneumonia (OP), NSIP-OP overlap and lymphocytic interstitial pneumonia (LIP)) classified according to IPAF Morphologic domain criteria. 8 Unexplained pulmonary vasculopathy was identified where available by right heart catheterization (RHC) demonstrating mean pulmonary artery pressure ≥25 mm Hg and capillary wedge pressure ≤15 mm Hg, as defined by IPAF criteria. 8 When RHC was not performed, forced vital capacity/diffusion capacity for carbon monoxide (FVC/DL CO ) ratio ≥1.6 was used to support possible pulmonary hypertension as previously described. 12 For each patient identified possibly meeting Morphologic Domain criteria for unexplained pleural effusion or thickening, unexplained pericardial effusion or thickening, unexplained intrinsic airway disease or unexplained pulmonary vasculopathy, careful review of the available clinical documentation was performed to identify an alternative or secondary cause, and where found, no credit was given. Collated data on the remaining 101 subjects included demographics, ever-smoking history, date of diagnosis and death or last date known alive. IPAF with UIP features (IPAF-UIP) was defined as those with biopsy confirmed UIP or UIP CT pattern based on the 2011 ATS/ERS radiological criteria. 11 Patients without a documented date of death were screened by United States Social Security Death Index (USSDI) on 1 August 2016, with this date used as a survival end point if death was not found. For comparative survival analysis, established IPF patients from the same observation period (n = 50) were randomly selected in a near 2:1 ratio to IPAF-UIP patients (n = 19). Survival analysis was performed between subgroups (IPAF-UIP and IPAF non-UIP) and IPF.
Statistical analysis was performed using JMP Software Version 10.0 (SAS Institute, Cary, NC, USA). Continuous data were reported as either mean or median with SD and range. Group comparisons were made with either chi-square or t-test and survival analysis was performed with Kaplan-Meier using log-rank test. Two-sided Pvalues <0.05 were considered statistically significant.
RESULTS
Of the 111 patients screened from previous 'UCTD-ILD' diagnoses, 101 met strict clinical criteria for IPAF and were included in the final analysis (91%). There was male predominance (61%) with a mean age of 56.9 years, the majority of whom were never-smokers (69%) ( Table 2) . Criteria for IPAF diagnosis was met through a combination of Clinical and Serologic Domains in 4 (4%), Clinical and Morphologic Domains in 14 (14%), Serologic and Morphologic Domains in 26 (26%) and all three domains in 57 (56%). Within the Clinical Domain, the most common sign or symptom was Raynaud's phenomenon (54.5%), followed by inflammatory arthritis/polyarticular morning stiffness (29.7%) and unexplained digital oedema (17.8%). None had Gottron's sign.
Frequency of positive laboratory findings meeting Serologic Domain criteria are presented in Table 2 . Antinuclear antibody (ANA) elevation was the most frequently positive finding at 39.6%. Of note, our institution does not routinely perform ANA titre or report a staining pattern unless specifically requested, thus this finding does not explicitly follow ERS/ATS criteria for IPAF, although need for positive ANA titre/pattern was not required for currently included patients to meet IPAF criteria. Of the laboratory findings specific to IPAF, anti-SSA was the most common (35.6%) followed by ANA ≥1:320 titre in a diffuse, speckled or homogenous pattern (18.8%). Anti-PM-Scl was negative in seven tested patients, with no testing performed for anti-MDA-5.
Elements of the Morphologic Domain are presented in Table 3 . NSIP was the most frequently identified radiological pattern occurring in 64.4% of patients. Biopsy was performed in 51 patients with UIP and OP being the most commonly identified pathological patterns (23.5% each). A majority (37.2%) of patients had unclassifiable or nondiagnostic pathological features. Among those with additional clinicomorphologic features, unexplained intrinsic airway disease manifesting as functional airflow obstruction on PFT, bronchiolitis or non-traction bronchiectasis occurred in 42.6% of patients. Of the 23 patients with evidence of airway obstruction, 10 (43%) were current or former smokers. Unexplained pericardial effusion was seen in 30 (29.7%) with pulmonary vasculopathy found in 39 (38.6%) patients.
Baseline characteristics of subjects with UIP on histopathology or CT pattern (n = 19) were compared with non-UIP IPAF patients and presented in Table S1 (Supplementary Information). Demographics and functional status were no different between IPAF-UIP and IPAF non-UIP subgroups with trend towards lower total lung capacity (TLC) % and DL CO % in IPAF-UIP. Frequency of positive Clinical and Serologic Domain findings were similar, while IPAF-UIP patients had decreased incidence of Morphologic Domain findings (79% vs 99%, P = 0.004). • ANA antibody (any titre) ANA, anti-nuclear antibody; GERD, gastro-oesophageal reflux disease; IPAF, interstitial pneumonia with autoimmune feature; LIP, lymphocytic interstitial pneumonia; NSIP, non-specific interstitial pneumonia; OP, organizing pneumonia; PFT, pulmonary function test; UCTD, undifferentiated connective tissue disease.
IPF patients (n = 50) were randomly selected at a near 2:1 ratio to IPAF-UIP patients (n = 19) from the same study period and compared for baseline clinical characteristics (Table S2 , Supplementary Information). IPF patients had higher incidence of ever-smoking history (66% vs 32%, P = 0.01), but other baseline demographic and PFT findings were similar.
Kaplan-Meier survival comparisons for IPAF-UIP, IPAF non-UIP and IPF are presented in Figure 1 . There was a statistically significant difference in survival among the three subgroups (log rank P < 0.0001). Survival in IPAF-UIP versus IPAF non-UIP appeared worse for IPAF-UIP (log rank P = 0.0418) and similar to IPF (log rank P = 0.08) when IPAF-UIP survival was compared between groups (Kaplan-Meier survival curves/data not shown).
DISCUSSION
We reviewed patients meeting strict ERS/ATS IPAF criteria culled from previously diagnosed broad UCTD-ILD and found IPAF in 91% of cases, of which those with UIP features either on CT or pathology made up 19%. The majority of diagnosed patients met criteria from all three diagnostic domains (56%) with Raynaud's phenomenon, positive ANA serology or titre and NSIP CT pattern dominating as domain-specific features, respectively. When stratified by those with UIP versus non-UIP features, IPAF-UIP subjects had statistically less frequent Morphologic Domain findings (P = 0.004), with the majority meeting IPAF criteria through positive Clinical and Serologic findings. Survival was better for IPAF non-UIP as compared with IPAF-UIP and IPF.
Clinical characteristics meeting strict IPAF criteria have been reported in three prior retrospective series assessing single-centre cohorts. Variation in findings may be reflective of local population referrals and methodology in the ascertainment of disease diagnosis. We found that only 19% of our cohort had features of UIP on either CT or pathology culling from previously diagnosed UCTD-ILD patients, as compared with a recent series where UIP was more prevalent (54.6% of CT findings and 61% of surgical lung biopsies, respectively) 10 culling from consecutive ILD. Chartrand et al. found similar UIP incidence to ours as defined by ANA, anti-nuclear antibody; DL CO %, percent diffusion capacity for carbon monoxide; FEV 1 %, percent forced expiratory volume in the first second; FVC%, percent forced vital capacity; IPAF, interstitial pneumonia with autoimmune feature; RF, rheumatoid factor; TLC%, percent total lung capacity.
histopathology (22%). 13 Our gender demographic was notably male predominant (61%) in contrast to females representing between 49.1% and 71% of other series. 10, 13, 14 Age at diagnosis in our patient population was similar to Chartrand et al. whose average age was 54.6 years, 13 but younger than that seen by Oldham et al. and Ahmad et al. in their two series whose mean ages were 63.2 and 64.4 years, respectively. 10, 14 Inflammatory arthritis dominated the Clinical Domain in one series, 14 with consistent findings between our cohort and the remaining series regarding most frequently positive individual domain findings.
Despite a smaller number of IPAF-UIP patients in our study, survival involving UIP appeared consistent with those of Oldham et al. where no difference was seen between IPAF-UIP and IPF. In contrast, our IPAF cohort overall appeared to have better survival compared with IPF. Ahmad et al. diagnosed IPAF in 57 patients, 19 (33%) of whom were found to have UIP features and found no difference in survival between IPAF and IPF in their series. 14 We found that IPAF-UIP patients in our study had similar baseline demographics and functional status compared with IPAF non-UIP, with only trend towards lower TLC% and DL CO %. When compared with control IPF patients, IPAF-UIP were also indistinguishable demographically and functionally. We did not assess frequency of IPAF domain findings in our comparison IPF cohort given their established diagnoses. No baseline demographic, clinical and functional findings were reported in prior series for those with IPAF-UIP. Of note, the frequency of UIP findings in all published series thus far reaches 45% (136 out of 302 reported, weighted predominantly by Oldham et al.'s study), suggesting significantly higher incidence of UIP than found in other CTD-ILD whose pathological or radiological findings are historically dominated by NSIP and NSIP-OP overlap. Current IPAF survival appears to be swayed towards behaving more like IPF depending on the incidence of UIP in each cohort. Chartrand et al. who reported similar UIP frequency to our study noted relatively stable disease over time based on follow-up FVC%. 13 Mounting evidence would suggest that the presence of UIP may be confounding in terms of IPAF diagnosis, and perhaps explicit UIP exclusion may not be unreasonable as the behaviour of IPAF-UIP appears similar to IPF.
We found using previous broad definitions of UCTD-ILD that IPAF criteria were met in 91% of cases. It would appear that the current IPAF criteria may be only slightly more restrictive and directed than prior broad UCTD criteria. This may explain the lower incidence of UIP findings in our cohort. Indeed, other IPAF series have reported a greater number of UIP findings when applying IPAF to all presenting ILD, perhaps attributable to the currently more inclusive or broader combinations of domain criteria. The question remains as to whether such included patients simply represent forme fruste IPF, given their similar clinical characteristics and survival, or a unique IPAF subcategory. While we did not compare IPAF survival to established CTD-ILD in our study, Oldham et al. noted better survival among those with confirmed CTD compared with all other groups except IPAF with non-UIP findings. 13 Our CT, computed tomography; IPAF, interstitial pneumonia with autoimmune feature; LIP, lymphocytic interstitial pneumonia; NSIP, non-specific interstitial pneumonia; OP, organizing pneumonia; PFT, pulmonary function test; UIP, usual interstitial pneumonia. institution has shown previously that CTD-UIP appears to do better than IPF, 15 although varying results have been previously reported. [16] [17] [18] In one study, CTD-UIP appeared to have similar survival to IPF; however, it was demonstrated that UCTD patients grouped within the CTD-ILD may have negatively impacted survival. 16 Of note, higher prevalence of positive autoimmune serology has been reported in IPF patients 19 and may confound IPF diagnosis by suggesting autoimmune disease. Prior studies have suggested positive serology may be as high as 29% in one review of biopsy-proven IPF, 20 and notably in one series involving 'autoimmune featured ILD', a predecessor to IPAF, there was no difference in overall survival for this subgroup when compared with IPF. 5 Our study has several limitations. First, a retrospective design while useful for collecting data in a timely manner and exploring disease findings has inherent limitations in terms of completeness of abstracted data and variable follow-up. A prospective study may perhaps better standardize diagnosis, and outline the true clinical course of disease and survival. Patients in our IPAF cohort also underwent a variety of empiric or directed treatments, which were not considered in the survival analysis and a prospective approach would be similarly better suited for this evaluation. Finally, our study screened patients from previously diagnosed UCTD-ILD using the broad definition, where prevalence of UIP or CT or pathology may be lower in comparison to applying IPAF criteria to all assessed ILD as seen in prior studies. Indeed, in clinical practice, application of such criteria would be more relevant in those with clinical or serological suspicion of autoimmune disease, which was the rationale for screening from previously broadly defined UCTD-ILD rather than consecutive ILD or those with already established CTD.
In conclusion, current IPAF criteria appear to encompass the majority of previously defined UCTD-ILD. Current evidence suggests enhanced survival when compared with IPF except in those with UIP findings on CT or pathology, in contrast to UIP seen in other CTD-ILD. Questions remain as to whether UIP should be considered exclusionary for IPAF diagnosis. Further studies are necessary to refine IPAF criteria for clinical use and guide future treatment and follow-up in terms of expected survival.
